Celgene Corporation
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 61.46 |
| 52 Week High | 77.39 |
| 52 Week Low | 41.26 |
| Avg. Daily Vol. (Mil) | 4.96 |
| Beta (3 year) | 0.43 |
| Share Related Items | |
| Mkt Cap (Mil) | 27,957.19 |
| Shares Out (Mil) | 454.88 |
| Float (Mil) | 453.15 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 6.20 |
| Current Ratio | 6.90 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 15.56 |
| Price/Book | 8.16 |
| Price/Cash Flow | -21.00 |
| Per Share Data | |
| Earnings | -3.45 |
| Sales | 3.95 |
| Book Value | 7.53 |
| Cash Flow | -2.92 |
| Business Summary | |
|---|---|
| A biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. | |
| General Information | |
| 86 Morris Avenue
Summit, NJ 07901 |
|
| www.celgene.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 1685 | |
| CEO: Dr. Sol J. Barer, Ph.D. | |
| Short Interest | |
| Current Month (Mil) | 10.19 |
| Previous Month (Mil) | 10.48 |
| Short Interest Ratio (Days) | 1.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -34.00 |
| Return on Investments | -41.00 |
| Profitability | |
| Gross Margin | 90.70 |
| EBIT Margin | -64.50 |
| Profit Margin | -78.20 |
Quotes
News & Commentary
Financials
Company Information
Ratings
Find more premium investing ideas